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Background: There is a growing need to offer persons with multiple sclerosis (PwMS) 
possibilities for self-management and to integrate multidisciplinary health data. In 2009–2014 
we developed a patient-reported outcome based, interactive, web-based program (MSmonitor) 
for (self-)monitoring, self-management and integrated, multidisciplinary care in MS.
Methods: The notions underlying the MSmonitor concept and the program’s elements are 
described. We analyze MSmonitor’s role in the self-management of fatigue by retrospective 
comparison of fatigue and health-related quality of life (HRQoL) before and after usage of 
specific elements of MSmonitor, and by a correlative analysis between frequency of usage and 
fatigue change.
Results: After a step-wise development the program comprises six validated questionnaires: 
Multiple Sclerosis Impact Profile, Modified Fatigue Impact Scale-5 items (MFIS-5), Hospital 
Anxiety and Depression Scale, Multiple Sclerosis Quality of Life-54 items, and the 8-item Leeds 
Multiple Sclerosis Quality of Life (LMSQoL) questionnaires; two inventories: Medication and 
Adherence Inventory, Miction Inventory; two diaries: Activities Diary, Miction Diary; and two 
functionalities: e-consult and personal e-logbook. The program is now used in 17 hospitals by 581 
PwMS and their neurologists, MS nurses, physical therapists, rehabilitative doctors, continence 
nurses, and family doctors. Those PwMS (N=105) who used the LMSQoL and MFIS-5 question-
naires at least twice in a period of up to 6 months, showed improved HRQoL (P,0.026). In the 
subgroup (N=56) who had also used the Activities Diary twice or more, the frequency of diary 
usage correlated modestly with the degree of fatigue improvement (r=0.292; P=0.028).
Conclusion: MSmonitor is an interactive web-based program for self-management and inte-
grated care in PwMS. Pilot data suggest that the repeated use of the short MFIS-5 and LMSQoL 
questionnaires is associated with an increase in HRQoL, and that a repeated use of the Activities 
Diary might contribute to the self-management of fatigue.
Keywords: multiple sclerosis, self-management, web-based, care, multidisciplinary, patient-
reported outcome
Introduction
Multiple sclerosis (MS) is a chronic inflammatory and degenerative disease of the central 
nervous system. In approximately 80% of the persons with multiple sclerosis (PwMS) the 
first clinical phase is characterized by recurrent episodes of new or worsening symptoms 
(relapses), which are typically followed by complete or partial remissions: relapsing 
remitting MS (RRMS). Anti-inflammatory immune-modulating or immune-suppressing 
drugs may substantially reduce the frequency and severity of relapses, and thus modify the 
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disease course of RRMS. However, the long-term outcome of 
disease modifying drug (DMD) treatment is largely unknown. 
After 10–15 years most persons with RRMS convert to the 
secondary progressive (SP) phase. It has not been elucidated 
to what degree DMDs may prevent or postpone the conver-
sion to SPMS. The SP phase is characterized by a slow but 
relentless increase in disability and rare or absent relapses. 
Approximately 15% of PwMS have a progressive course from 
disease onset: primary progressive MS. In both SPMS and 
primary progressive MS DMDs are not effective.
Epidemiological studies in RRMS indicate that the 
interval from disease onset to the occurrence of irreversible 
major disabilities (walking with aid, being wheelchair bound) 
depends on the time interval between disease onset and the 
attainment of lower disability levels (limited walking but 
without aid); and that the time to reach these lesser disabili-
ties depends on the inflammatory disease activity in the first 
2 years after diagnosis.1–3 This means that there is an early 
and limited therapeutic window, and that to optimally prevent 
long-term disability, DMDs should be used strategically and 
efficiently. This requires a close clinical monitoring, in order 
to assess any increase in disability, due to incomplete recov-
ery of relapses, or any worsening of health-related quality 
of life (HRQoL), an overall subjective measure of effective-
ness, as well as to detect side effects.4,5 The require ments for 
intense monitoring may not be fully met by doctor-centered 
measurements during regular outpatient visits. More frequent 
assessments and the use of patient-reported outcomes (PROs) 
could have an added value.6,7 
In MS, the lesions in the central nervous system are mul-
tifocal and widespread. Depending on the actual localization 
of lesions PwMS may experience a great variety of symptoms 
and signs. Therefore, MS treatment is typically multidisci-
plinary, involving medical specialists, specialized nurses, and 
other paramedical disciplines. Thus, the multidisciplinary 
team of health care professionals may include a neurologist, 
registered nurse specializing in MS, psychologist, physical 
therapist, occupational therapist, ophthalmologist, reha-
bilitation specialist, dietician, gastroenterologist, and others. 
Moreover, as it is largely unpredictable whether or when a 
specific problem may occur, MS care and counseling should 
be flexible and personalized.
In PwMS the accumulation of disabilities leads to the 
loss of independence, which in turn may negatively affect 
autonomy and self-efficacy.8–10 Low self-efficacy has been 
associated with lower HRQoL11,12 and less physical activity.12 
Since a lowered self-efficacy causes PwMS to undervalue 
their actual capabilities, a vicious circle may start and 
still existing functions run a risk to eventually disappear. 
Self-efficacy may be increased via self-management. In 
general, self-management comprises interventions, educa-
tion, training, and skills by which patients with a chronic 
condition, disability, or disease can effectively take care of 
themselves and learn how to do so.13 Given that the onset of 
MS is often in early adulthood, PwMS could substantially 
benefit from early adopted self-management strategies.
In view of the aforementioned considerations we set 
out to develop an interactive web-based program for self-
management and professional multidisciplinary care in MS, 
and we explored the program’s role in self-management.
Methods
concept
The concept of the MSmonitor program is based on three 
notions: the autonomy of PwMS; the multidisciplinary 
character of MS care; and a collaboration of the stakeholders 
involved in MS care.
Autonomy of PwMs
Autonomy is the capacity to make informed un-coerced 
decisions, and is the basis of the responsibility and account-
ability for one’s actions. In PwMS, autonomy is the basis for 
self-management and shared decision making. By facilitating 
self-assessments, self-monitoring, and self-management, the 
MSmonitor program aims to utilize and increase PwMS’ 
autonomy. The fact that PwMS own their personal data 
generated by MSmonitor and decide on which health care 
professional to authorize access to the data, is in line with 
autonomy as a leading principle of MSmonitor.
Multidisciplinary care
From the PwMS’ perspective, health care is not organized to 
efficiently provide multidisciplinary care. In daily practice 
the communication between health care professionals may be 
inadequate, leading to deficient quality of care or repetition 
of measurements. By making the self-assessments’ results 
available to all authorized members of the multidisciplinary 
team, the MSmonitor program prevents unnecessary assess-
ments and enables an optimal use of PROs. Moreover, the 
e-consult functionality facilitates communication between 
PwMS and health care professionals, and between profes-
sionals mutually.
collaboration of stakeholders
MSmonitor has been developed step by step by the immaterial 
and material input of various stakeholders: 1) PwMS, 
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2) health care professionals, 3) hospitals, 4) a software 
company (Curavista bv), 5) a research institute (MS4 
Research Institute), 6) a Scientific Advisory Board, and 
7) funding partners (TEVA, Sanofi-Aventis). The synergy 
of the collaboration between PwMS, professionals, and 
public and private organizations results from their combined 
respected expertise and input. The collaboration is dynamic 
and developing, has a minimum of formalization – which 
promotes flexibility and creativity – and is based on the 
endorsement by each participant of the MSmonitor concept. 
The MSmonitor Working Group includes all neurologists and 
MS nurses that use MSmonitor. Curavista bv (AK, EvN) is a 
commercial software company specializing in health appli-
cations and online assessments in acute and chronic health 
disorders. The MS4 Research Institute (PJJ) is an independent 
scientific not-for-profit organization dedicated to e-health 
research, especially in MS. TEVA and Sanofi-Aventis are 
pharmaceutical companies manufacturing DMDs.
The aspects to be monitored and the program’s 
elements were suggested by PwMS, neurologists, and 
nurses. Which tool to use for assessing a certain aspect, was 
primarily suggested by neurologists and nurses, based on 
their experiences and preferences. Then, the MS4 Research 
Institute checked the psychometric validity of the sug-
gested tool, based on a review of the literature. The final 
choice was made by the MSmonitor Working Group and 
approved by the Scientific Advisory Board. The members 
of the Scientific Advisory Board are Stephan T Frequin 
PhD, neurologist (St Antonius Hospital, Nieuwegein, 
the Netherlands), Dianne Groenewoud, epidemiologist 
(Nijmegen, the Netherlands), Kitty Harrison RN 
MANP, MS nurse (Tergooi Ziekenhuizen, Blaricum, the 
Netherlands) and Dorothea Heersema PhD, neurologist 
(University Medical Centre Groningen, Groningen, the 
Netherlands).
content and availability
At the time of study (2014) MSmonitor’s content comprised 
nine components and two functionalities in five categories: 
1) questionnaires, 2) inventories, 3) diaries, 4) e-consult, and 
5) personal e-logbook. In line with the autonomy principle, 
it was not predefined which patients should use what part 
of the program and when. The actual use of the various ele-
ments differed between the centers and also depended on the 
neurologists’ and nurses’ preferences. For example, some 
centers focused on the use of the Multiple Sclerosis Impact 
Profile (MSIP) for their regular outpatient consultations, 
others on the use of the Miction Inventory.
Questionnaires
The questionnaires are psychometrically validated and 
include the MSIP, Multiple Sclerosis Quality of Life-54 
(MSQoL-54), Modified Fatigue Impact Scale-5 Item Ver-
sion (MFIS-5), Leeds Multiple Sclerosis Quality of Life 
(LMSQoL), and the Hospital Depression Anxiety Scale 
(HADS).
The MSIP comprises 36 questions assessing disability 
(Q1a–Q36a) and disability perception (Q1b–Q36b) in seven 
domains (muscle and movement functions, excretion and 
reproductive functions, basic movement activities, activities 
of daily living, participation in life situations, environmental 
factors, mental functions) and four symptoms (fatigue, pain, 
speech, vision).14–16 In addition to yielding validated domain 
and symptom scores, the MSIP provides a complete overview 
of MS-related symptoms and their subjective valuation. 
Completion time is approximately 20 minutes.
The MSQoL-54 provides an MS-specific, multi-
dimensional assessment of patient-centered health status, 
and consists of the Short Form 36-Item health survey as 
a generic core measure, supplemented with 18 questions 
on items relevant to PwMS in the areas of health distress, 
sexual function, satisfaction with sexual function, overall 
QoL, cognitive function, energy, pain and social function.17 
The MSQoL-54 contains 52 items distributed into 12 scales, 
and two single items. A physical and a mental dimension 
underlie the MSQoL-54: the physical and mental domains.17 
Completion time is approximately 15 minutes.
The MFIS-5 is a short, 5-item questionnaire examining a 
patient’s perceived impact of fatigue on a variety of daily activi-
ties over the past month.18 Answers to each question are rated 
on a 5-point scale from 0 to 4. The MFIS-5 total score consists 
of the sum of the raw scores on these five items and ranges 
from 0 to 20, where higher scores indicate more experienced 
fatigue.18 Completion time is approximately 2 minutes.
The LMSQoL is a self-assessment scale that consists of 
eight questions, examining MS-related aspects of QoL over 
the past month.19,20 Answers are rated on a 4-point scale from 
0 to 3 an the resulting score ranges from 0 to 24, with higher 
scores reflecting higher levels of well-being. Completion time 
is approximately 2 minutes.
The HADS is a 14-item, self-report questionnaire for anx-
iety and depression.21 The HADS consists of two subscales, 
one for anxiety and one for depression, each comprising seven 
questions. Completion time is approximately 5 minutes.
For all questionnaires scores are automatically generated 
by the program and presented in graphs and tables to PwMS 
and their authorized caregivers.
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inventories
Inventories provide complete overviews and do not generate 
scores. The Miction Inventory consists of an overview of 
urological symptoms known to occur in MS. The Medication 
and Adherence Inventory gives a patient-reported update of 
medication that is taken, the number of missed DMD doses 
in the last month, and the date and reason of an eventual 
DMD discontinuation.
Diaries
Diaries are meant to give insight into MS-related processes 
over 24-hour periods. The Activities Diary records the type 
and duration of activities and rest periods. The Miction 
Diary documents the frequencies and quantities of mictions 
and fluid intakes.
e-consult
The e-consult functionality enables PwMS to contact their 
health care professionals, to ask questions or provide feed-
back, and enables professionals to communicate mutually.
e-logbook
The e-logbook functionality is a personal e-diary for record-
ing items or experiences that are not covered by the standard-
ized questions of the questionnaires or inventories. It has the 
option to set personal goals for self-management.
standard availability
The MSIP, MSQoL-54, MFIS-5, and LMSQoL question-
naires, Medication and Adherence Inventory, diaries, 
e-consult, and e-logbook are available to all participating 
PwMS. The MFIS-5, LMSQoL, and Medication and Adher-
ence Inventory can be used monthly; the MSIP at least 
6-monthly and at most monthly (depending on the choice 
of the center); the MSQoL-54 annually; the diaries and 
e-logbook daily; and the e-consult whenever needed.
The use of LMSQoL, MFSI-5, and Medication and 
Adherence Inventory (“Quickscan”) enables quick monthly 
assessments of one’s HRQoL, experienced fatigue, medica-
tion, and adherence.
selective availability
The completions of the HADS and Miction Inventory are 
indicated by the health care professionals. The HADS is made 
available by neurologist, MS nurse or psychologist on clinical 
indication, eg, when suspecting an anxiety or mood disorder, 
or for evaluating the effectiveness of a treatment. In case of a 
sub-score .8, an alert is presented on the dashboard to warn 
about the abnormal finding. The Miction Inventory is made 
available by neurologist, MS nurse, urologist or continence 
nurse on indication.
recent developments
A recent user of the MSmonitor program is the not-for-profit 
organization MS Care Netherlands (MS Zorg Nederland). 
One of the activities of MS Care Netherlands is the devel-
opment of regional multidisciplinary networks of qualified 
health care professionals in the field of MS. Its primary goal 
is that optimal multidisciplinary professional care for PwMS 
is available locally and in every phase of the disease. To 
this end, MS Care Netherlands organizes regional training, 
education, and certification of health care professionals, and 
develops multidisciplinary guidelines for MS care processes. 
The first five regional networks started in October 2013 with 
200 health care professionals being trained in providing 
optimal care for approximately 2,000 PwMS. In 2014, five 
additional regional networks started, bringing the total of 
certified health care professionals to 400. The ultimate goal 
of MS Care Netherlands is to establish multidisciplinary 
regional networks in every region of the Netherlands. The 
use of the MSmonitor program is thought to facilitate the 
extramural implementation of multidisciplinary and per-
sonalized treatment programs via exchange of information 
and sharing PROs.
Recently the applications of the short questionnaires, 
e-consult, and diaries for smart phones have been imple-
mented (Figure 1). The mobile use of selected components 
is thought to improve the self-management, screening, and 
communication options of the program. The full use, includ-
ing longer questionnaires, is conceivably best realized via 
tablets, laptops or desktops. It is of note that in PwMS motor, 
sensory, coordinative, or visual symptoms may interfere 
with smart phone use and thus limit the applicability of the 
mobile option.
The prevalence of urological symptoms is high in MS, 
affecting 80%–100% of the PwMS during the course of 
the disease.22 In 2013 a self-screening tool for neurogenic 
bladder overactivity (Actionable questionnaire) was 
developed.23,24 This 8-item questionnaire is a reliable, 
sensitive, and specific screening tool for people with blad-
der problems related to MS.23,24 It may be especially use-
ful in identifying PwMS who could benefit from further 
urologic evaluation and treatment.23,24 In 2015, a Dutch 
version of the Actionable questionnaire was validated. We 
imagine that PwMS screen themselves online on a regular 
basis or after the occurrence of (new) bladder symptoms. 
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A positive screening may be followed by an e-consult, 
completion of the Miction Diary and Miction Inventory or 
self-management.
The neurological assessment of disabilities is essential 
to the monitoring of MS disease activity. The Expanded 
Disability Status Scale (EDSS) is widely used in clinical 
studies and neurological practice.25,26 The EDSS is a single, 
ordinal, non-linear composite score based on observer-
rated scales in seven neurological functional systems, and 
ambulation.26 In 2013, the Medisch Centrum Leeuwarden 
started the implementation of the Treatment Optimization 
Recommendations of the Canadian Multiple Sclerosis Work-
ing Group.27 This gave rise to the inclusion of the EDSS in 
the MSmonitor program.
With the growing numbers of participating hospitals and 
PwMS the quantity of patient-reported data is rapidly increas-
ing. Actually MSmonitor counts 1,500 visits per month and 
150 completed forms per week. Consequently, we envisage 
to analyze the MSmonitor data base for research purposes. 
Moreover, PwMS may be contacted by their neurologist or 
nurse via the “mail-to-all” function, to be informed about 
a study or survey. Persons who want to participate confirm 
their participation online after having read the informed con-
sent page, and fill in the research questionnaire. Additional 
patient-reported data, eg, on relapses, can be obtained in the 
context of study protocols.
Technical, security, and ethical aspects
The MSmonitor program is a modular application on the 
Curavista e-Health Platform, built on an Oracle database with 
JAVA-scripting, XML-applets and AJAX protocols. Data 
processing is 256-bits encrypted with VPN-tunneling. The 
databases are physically and software secured in a dedicated 
data center in the Netherlands. Prior to participation PwMS 
give electronic consent for storage of personal data and their 
responses in the database, for access to data by attending 
health care professionals of their choice, and for analyses 
of anonymized and aggregated data for scientific or policy 
purposes (eg, to improve the content of MSmonitor). The 
reasons for data analyses are checked by an independent 
supervisory board (Stichting Infometer). It is possible for 
PwMS to participate in MSmonitor without giving consent 
for data analyses. The MSmonitor project and the protocol 
for analysis of the pilot data were not reviewed by an ethical 
committee, as they did not qualify for being tested according 
to the Dutch Medical Research Involving Human Subjects 
Act of 1999 (http://wetten.overheid.nl/BWBR0009408).28
Data analysis
To explore the potential value of the MSmonitor program 
with respect to the self-management of fatigue, we analyzed 
the relationships between the levels of fatigue (MFIS-5) and 
HRQoL (LMSQoL) on the one hand, and the usage of the 
Activities Diary on the other. We hypothesized, first, that 
the usage of the diary was associated with a decrease in 
fatigue and an increase in HRQoL; second, that the frequency 
of diary usage was associated with the degree of fatigue 
decrease and HRQoL increase; and, third, that the mere use 
of the MFIS-5 and LMSQoL (self-assessment per se) in 
the Quickscan was associated with an increase in HRQoL. 
Moreover, we hypothesized that the frequency of Activities 
Diary usage was associated with worse MFIS-5 and LMSQoL 
scores at baseline, and better scores at the last assessment. 
PwMS who had used the Quickscan at least twice in a 
period of maximal 6 months, were included in the analy-
ses. For both the MFIS-5 and the LMSQoL, the difference 
between the first and last score was tested with paired 
Student’s t-tests. Spearman coefficients were calculated for 
Figure 1 screenshot of Msmonitor patient dashboard for iOs and Android smart 
phones.
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the correlations between the frequency of Activities Diary 
usage, and the MFIS-5 and LMSQoL scores (first score, 
last score, difference). In line with the explorative character 
of the analyses in all tests a P-value ,0.05 was considered 
significant.
Results
Development
The development of the MSmonitor program was practice-
based in real life settings with no predefined inclusion or 
exclusion criteria for participation of PwMS or hospitals. 
It started in September 2009 in the Medisch Centrum 
Leeuwarden with the MFIS-5 and LMSQoL questionnaires, 
both used previously in the online OPTIVIT study6 and the 
Medication and Adherence Inventory. The annual increases 
in the number of hospitals and PwMS using the program, 
and in the number of the program’s elements are presented 
in Figure 2. In the period 2009–2014 (April), the numbers 
of participating hospitals in the consecutive years were 1, 2, 
9, 9, 12, and 17; the number of participating patients were 
56, 264, 422, 470, and 581; and the number of components 
4, 6, 10, 10, 11, and 11. 
Participation
Neurologists and nurses informed PwMS about MSmonitor 
during outpatient visits. In line with the open, practice-
based character of the pilot phase, there were no predefined 
eligibility criteria for participation. PwMS who agreed to 
participate in the program were registered online by their 
neurologist or nurse. Of the 510 PwMS who had been regis-
tered as users by March 2013, 470 PwMS had actually started 
using MSmonitor, with the following characteristics: mean 
(standard deviation [SD]) age of 47.7 (12.1) years; number 
of female PwMS 391 (83.2%) – mean (SD) age 45.8 (12.1) 
years – and of male PwMS 79 (16.8%) – mean (SD) age 51.3 
(11.1) years (Figure 3). 
Nine disciplines of health care professionals used the 
program, including neurologists (n=26), MS nurses (n=21), 
physical therapists (n=9), rehabilitation doctors (n=5), con-
tinence nurses (n=2), nurse practitioners (n=2), research 
nurse (n=1), family physician (n=1), and physician assistant 
(n=1). The multidisciplinary use of the program may prevent 
unnecessary assessments and improve communication. For 
example, the neurologist, MS nurse, and continence nurse 
all have access to the Miction Diary and Miction Inventory 
outcomes, whereas the continence nurse is responsible for 
the interpretation of the data and for eventual diagnostic 
and therapeutic actions; information about patients with 
abnormal Miction Diary or Miction Inventory findings are 
safely communicated via the e-consult functionality. The 
Dutch guidelines for rehabilitation doctors with respect to 
MS include the MSIP, which is also used by neurologists 
and MS nurses for their regular outpatient visits; by using the 
MSmonitor program, the patient is prevented from having to 
complete the MSIP twice.
self-management of fatigue
One-hundred-and-five PwMS met the criteria for being 
included in the analysis: they had completed the MFIS-5 and 
LMSQoL questionnaires two or more times in a period of 
maximal 6 months. Their minimum age was 22.6 years and 
the maximum age 68.2 years (mean 44.2 [10.6] years). The 
mean age of males (49.7 [11.2] years) was higher than that 
of females (mean 43.4 [10.3] years) (P=0.033).
The numbers of PwMS according to sex and frequency 
of Activities Diary completion are presented in Table 1. 
Figure 2 growth patterns of the number of hospitals (blue bar) and patients (red bar) participating in the Msmonitor program and of the number of program elements 
(green bar) in the pilot phase from 2009 (0%) to 2014 (100%).
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The ages in the groups with none, one, and two or more 
diary completions showed no differences (P=0.57). The 
interval between the first and the last MFIS-5 and LMSQoL 
completions ranged between 3 and 183 days (mean 110.8 
[52.5] days). The intervals did not differ between the three 
groups (P=0.065). 
The MFIS-5 scores at first and last assessment, and the 
difference between the first and last assessment, in the groups 
with none, one, and two or more diary usages are shown in 
Table 2. 
There were no significant changes over time in MFIS-5 
score in either group. The corresponding values of the 
LMSQoL scores are shown in Table 3. 
In all three subgroups the mean LMSQoL score had sig-
nificantly improved (P=0.0255, P=0.0147, and P=0.0002, 
respectively) by 8.97%, 12.72%, and 10.06%, respectively. 
In those PwMS (N=56) who had used the Activities Diary at 
least twice, there was a modest, albeit statistically significant 
correlation between the frequency of diary usage and the 
decrease in MFIS-5 score (r=0.292; P=0.028). Correlations 
between diary usage and baseline MFIS-5 score (r=-0.123) 
and between diary usage and MFIS-5 score at last assess-
ment (r=0.051) were not significant (P=0.367 and P=0.711, 
respectively). Similar analyses for the LMSQoL scores 
yielded no significant correlations.
In all, the findings from these explorative analyses suggest 
that the self-assessment of fatigue and HRQoL is associated 
with an increase in HRQoL, and that the use of the Activity 
Diary may contribute to a decrease in fatigue.
Discussion
In a period of 5 years we gradually developed a web-based 
program for self-management and multidisciplinary care in 
MS, which comprises questionnaires, inventories, diaries, 
e-consult, and an e-logbook. The questionnaires quantita-
tively assess MS-related disabilities, perception of disabili-
ties, mental, physical and overall HRQoL, fatigue, anxiety, 
and depression; the inventories encompass medication, DMD 
adherence, and urological symptoms; and the diaries record 
activities and rest periods, and miction and fluid intake. 
The demographic characteristics showed that the female-
to-male ratio of the MSmonitor population is almost 5:1 
(4.95:1), which is higher than the overall female-to-male ratio 
in PwMS reported in the literature. In fact, a relatively rapid 
increase in the sex ratio among PwMS has been reported,29 
and a meta-analysis of epidemiological studies showed that 
the worldwide female-to-male ratio of MS did substantially 
increase over the last century from lower than two to more 
than three.30 In 2013, Boström et al investigated sex ratio 
trends of MS in Sweden using the National Swedish MS 
register, and found mean sex ratios of 2.62 in the analysis by 
year of birth (performed between 1931 and 1985) and 2.57 
in the analysis by year of onset (performed between 1946 
and 2005).31 In New Zealand, studies performed between 
1968 and 2001 consistently reported a female-to-male ratio 
of 2.5:1 to 3:1.32 In all, even the higher end of the increased 
female-to-male ratio range reported recently, is lower than the 
Figure 3 Flow chart showing the numbers of patients registered, using, and not 
using the Msmonitor program, and the numbers of patients who had used the 
MFis-5 and lMsQol questionnaires two or more times in a 6-month period. 
Abbreviations: MFIS-5, Modified Fatigue Impact Scale-5; LMSQoL, Leeds Multiple 
sclerosis Quality of life.
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Table 1 numbers of PwMs who used the Quickscan (including the MFis-5 and lMsQol questionnaires) at least twice in a period of 
maximal 6 months, according to sex and frequency of Activities Diary completion (0, 1 or 2)
Sex Numbers
No completion Activities Diary One completion Activities Diary Two or more completions Activities Diary Total
Male 5 1 10 16
Female 22 21 44 87
Unknown 0 0 2 2
Total 27 22 56 105
Note: For the total group the male-to-female ratio is 1:5.4.
Abbreviations: PwMS, persons with multiple sclerosis; MFIS-5, Modified Fatigue Impact Scale-5; LMSQoL, Leeds Multiple Sclerosis Quality of Life.
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ratio in the MSmonitor population. So, it seems that female 
PwMS were either preferentially invited to participate or 
were more prone to use MSmonitor.
Analysis of the pilot data on fatigue, overall HRQoL, and 
Activities Diary usage showed results that were in line with 
the notion that self-management via the MSmonitor program 
may be beneficial to PwMS: we observed that the use of the 
two short questionnaires MFIS-5 and LMSQoL was associ-
ated with an increase in HRQoL, and that the frequency of 
Activities Diary usage correlated with the degree of fatigue 
improvement. In persons with asthma it has been known, 
for over 2 decades, that guided self-management as part of 
systematic, planned care can lead to improvements in patient 
outcomes such as confidence to manage asthma and improved 
HRQoL, as well as reductions in hospitalizations, emergency 
room visits, unscheduled visits to the doctor, and days off 
work or school.33 Self-management for MS is a rather recent 
development, a situation that may partly relate to the variety 
and complexity of MS symptoms. Fatigue is one of the most 
frequently reported symptoms, interfering with functioning 
and resulting in activity limitations and participation 
restrictions.34 As fatigue may also be a side effect of the 
IFN-beta group of first-line DMDs, it may be difficult for 
PwMS, neurologists, and nurses to interpret this symptom. 
The Quickscan, which includes the MFIS-5, LMSQoL, and 
the Medication and Adherence Inventory, enables monthly 
assessments of one’s experienced fatigue, HRQoL, DMD 
medication and adherence. In combination with e-education, 
these tools may give PwMS a better insight into potential 
relationships between their levels of fatigue, the overall 
subjective well-being, medication (change) and adherence. 
PwMS may then adopt a strategy to self-manage their fatigue. 
Therefore, with the possibilities created by interactive web-
based programs, self-management may become a corner 
stone of disease management in MS.
The data generated online by PwMS are thought to also 
improve the quality and efficiency of multidisciplinary care. 
For example, the MSIP provides a complete overview of 
MS-related symptoms and their subjective valuation, and in 
MSmonitor the MSIP is completed a few days before an out-
patient visit. This has several advantages: PwMS are forced 
to reflect on their symptoms and thus prepare themselves for 
Table 2 First and last MFis-5 scores in a period of maximal 6 months and their difference in Quickscan groups with none, one, and 
two or more Activities Diary completions
Activities Diary completions N MFIS-5 score Mean SD Minimum Median Maximum
0 27 First 10.48 4.34 0.00 11.00 17.00
last 10.44 3.53 5.00 10.00 18.00
∆ -0.04* 2.93 -7.00 0.00 6.00
1 21 First 12.19 5.13 1.00 12.00 20.00
last 12.24 4.74 2.00 13.00 19.00
∆ -0.05* 2.87 -5.00 -1.00 7.00
2 or more 56 First 11.45 4.11 0.00 12.00 20.00
last 11.02 4.19 0.00 11.50 20.00
∆ -0.43* 2.53 -6.00 0.00 6.00
Notes: higher scores indicate more fatigue. *P.0.05 for comparison between first and last score. ∆= last minus first score.
Abbreviations: SD, standard deviation; MFIS-5, Modified Fatigue Impact Scale-5.
Table 3 First and last lMsQol scores in a period of maximal 6 months and their difference in Quickscan groups with none, one, and 
two or more Activities Diary completions
Activities Diary completions N LMSQoL score Mean SD Minimum Median Maximum
0 27 First 20.34 3.75 8.96 20.96 26.00
last 21.79 3.56 8.96 21.92 26.96
∆ 1.45* 3.17 -5.04 0.96 10.00
1 21 First 19.15 4.32 13.04 19.04 26.96
last 21.05 3.40 14.96 21.92 26.96
∆ 1.90** 3.23 -4.08 2.88 7.92
2 or more 56 First 20.38 3.62 12.08 20.00 26.96
last 22.16 4.01 13.04 21.92 27.92
∆ 1.78*** 3.28 -5.04 1.10 12.00
Notes: higher scores indicate more well-being. *P=0.0255; **P=0.0141; ***P=0.0002. P-values for comparisons between first and last score. ∆= last minus first score.
Abbreviations: SD, standard deviation; LMSQoL, Leeds Multiple Sclerosis Quality of Life.
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the onsite consultation; PwMS and professionals can view 
the completed MSIP questions, the automatically generated 
domain scores, and their graphic representation prior to 
the consultation; items and domain scores that have wors-
ened compared to the previous assessment are visualized by a 
color, and are summarized on the dashboard. The overview of 
worsened symptoms and their subjective evaluation (disabil-
ity perception) guides the consultation, and thus the efficiency 
and quality of multidisciplinary care may improve.
An interesting finding was that of the 385 PwMS who 
used the Quickscan, 150 (39.1%) were treated with a DMD. 
This observation contradicts the opinion that the use of self-
assessment programs is biased towards those PwMS who are 
treated with a DMD, and that persons with no such treatment 
are less prone to self-assessments due to them having a low 
disease activity or short disease duration. Moreover, the 
supposition that persons with progressive MS would not be 
interested in self-assessments, given their rather predictable 
disease course, seems not to be in agreement with our data.
Recent developments of MSmonitor include the use 
by regional networks of qualified professionals for multi-
disciplinary patient-centered care (MS Care Netherlands), 
smart phone applications, a self-screening tool for bladder 
function, the input of neurological data, and data analysis 
for research purposes. In fact, the combined registration of 
PROs, neurological and radiological data, and professional 
health care data seems to qualify the MSmonitor program 
for being used as (part of) a registry. The efficiency of the 
MSmonitor program, by using the same PROs for self-
management, professional care, and research purposes, is 
thought to constitute positive feedback for those who are 
expected to fill the registry with data, and to stimulate PwMS 
and health care professionals to continue their data input.
Finally, now the pilot phase has ended we will in the 
next years focus on three main topics: first, a further embed-
ding of the program in the regular care process; second, the 
development of a 2.0 version and a user’s guide, containing 
eg, information on minimally important differences that 
represent clinically relevant changes for the various scores; 
and, third, to analyze the usage by PwMS of the various 
components and functionalities in relation to demographic, 
disease, and personal characteristics.
Conclusion
MSmonitor is an interactive web-based program, developed 
for self-management and multidisciplinary professional care 
in MS. Pilot data seem to support the notion that MSmonitor 
may improve self-management by PwMS.
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